Miniatura

Fitxers

666380.pdf (2.15 MB)
666380 Erratum.pdf (333.91 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2016-06-08

Llicència de publicació

cc-by (c) Ripoll Llagostera, Èlia et al., 2016
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/120023

JAK3-STAT pathway blocking benefits in experimental lupus nephritis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13075-016-1034-x

Resum

Background: Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway and how CP-690,550 treatment influences LN outcome. Methods: Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and circulating cytokine changes. Results: CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli. We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating inflammatory cytokines were also reduced with treatment. Conclusions: On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune diseases.

Descripció

Es va publicar un erratum de l'article a: Arthritis Research & Therapy, 2016, vol. 18 , num. 1, p. 152

Matèries

Lupus, Malalties autoimmunitàries, Citoquines, Ratolins (Animals de laboratori)

Matèries (anglès)

Lupus, Autoimmune diseases, Cytokines, Mice (Laboratory animals)

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

RIPOLL LLAGOSTERA, Èlia, RAMON, Laura de, BORDIGNON DRAIBE, Juliana, MERINO, Ana, BOLAÑOS, Núria, GOMÀ, Montse, CRUZADO, Josep ma., GRINYÓ BOIRA, Josep m., TORRAS AMBRÒS, Joan. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. _Arthritis Research & Therapy_. 2016. Vol. 18, núm. 1, pàgs. 134. [consulta: 6 de febrer de 2026]. ISSN: 1478-6362. [Disponible a: https://hdl.handle.net/2445/120023]

Exportar metadades

JSON - METS

Compartir registre